Lack of Effect of Oral Sulforaphane Administration on Nrf2 Expression in COPD: A Randomized, Double-Blind, Placebo Controlled Trial
Wise RA, Holbrook JT, Criner G, Sethi S, Rayapudi S, Sudini KR, Sugar EA, Burke A, Thimmulappa R, Singh A, Talalay P, Fahey JW, Berenson CS, Jacobs MR, Biswal S, Broccoli Sprout Extract Trial Research Group
PloS one · 101 citations
How it was studied
- Design
- Randomized controlled trial (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
- Intake measured by
- Not stated
Who paid for it
- Funding
- Independent funding
- Government
- National Heart, Lung, and Blood Institute
- Government
- NHLBI NIH HHS
- Grants
- National Heart, Lung, and Blood Institute (U01 HL105569); National Heart, Lung, and Blood Institute (5U01HL105569)
Based on 2 listed funder(s) and full-text disclosure statement.
Publication
- Published
- 2016-11-10 · PLoS One · vol. 11 · issue 11 · p. e0163716
- Publisher
- Public Library of Science
- Cited
- 121 citations · more than 96% of similar papers · 5.1× the field average
- Impact
- Top 10% most cited in its field
- References
- 33 works
- Access
- Open access (journal) · CC-BY
- Research areas
- Genomics, phytochemicals, and oxidative stress · Curcumin's Biomedical Applications · Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Keywords
- Sulforaphane, COPD, Placebo, Medicine, Oxidative stress, Inflammation, Internal medicine, Randomized controlled trial, Pulmonary function testing, Immunology, Gastroenterology, Pathology, Cancer research
- MeSH
- humans, pulmonary disease, chronic obstructive, isothiocyanates, sulfoxides, administration, oral, double-blind method, gene expression regulation, oxidative stress, aged, middle aged, female, male, nf-e2-related factor 2
15 authors
From US
- Robert A. Wise · correspondingJohns Hopkins University; Johns Hopkins Medicine
- Janet T. HolbrookJohns Hopkins University
- Gerard J. CrinerTemple University
- Sanjay SethiVA Western New York Healthcare System
- Sobharani RayapudiJohns Hopkins University
- Kuladeep R. SudiniJohns Hopkins University
Abstract
Background
COPD patients have high pulmonary and systemic oxidative stress that correlates with severity of disease. Sulforaphane has been shown to induce expression of antioxidant genes via activation of a transcription factor, nuclear factor erythroid-2 related factor 2 (Nrf2).
Methods
This parallel, placebo-controlled, phase 2, randomized trial was conducted at three US academic medical centers. Patients who met GOLD criteria for COPD and were able to tolerate bronchoscopies were randomly assigned (1:1:1) to receive placebo, 25 μmoles, or 150 μmoles sulforaphane daily by mouth for four weeks. The primary outcomes were changes in Nrf2 target gene expression (NQ01, HO1, AKR1C1 and AKR1C3) in alveolar macrophages and bronchial epithelial cells. Secondary outcomes included measures of oxidative stress and airway inflammation, and pulmonary function tests.
Results
Between July 2011 and May 2013, 89 patients were enrolled and randomized. Sulforaphane was absorbed in the patients as evident from their plasma metabolite levels. Changes in Nrf2 target gene expression relative to baseline ranged from 0.79 to 1.45 and there was no consistent pattern among the three groups; the changes were not statistically significantly different from baseline. Changes in measures of inflammation and pulmonary function tests were not different among the groups. Sulforaphane was well tolerated at both dose levels.
Conclusion
Sulforaphane administered for four weeks at doses of 25 μmoles and 150 μmoles to patients with COPD did not stimulate the expression of Nrf2 target genes or have an effect on levels of other anti-oxidants or markers of inflammation.
Trial registration
Clinicaltrials.gov: NCT01335971.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC0).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.